KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Tax Provisions: 2012-2025

Historic Tax Provisions for Jazz Pharmaceuticals (JAZZ) over the last 13 years, with Sep 2025 value amounting to -$242.4 million.

  • Jazz Pharmaceuticals' Tax Provisions fell 1568.09% to -$242.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$332.7 million, marking a year-over-year decrease of 399.34%. This contributed to the annual value of -$91.4 million for FY2024, which is 23.75% up from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Tax Provisions stood at -$242.4 million for Q3 2025, which was down 1,261.93% from -$17.8 million recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Tax Provisions registered a high of $228.6 million during Q2 2021, and its lowest value of -$242.4 million during Q3 2025.
  • Its 3-year average for Tax Provisions is -$47.2 million, with a median of -$27.5 million in 2023.
  • Its Tax Provisions has fluctuated over the past 5 years, first spiked by 317.19% in 2021, then crashed by 2,958.96% in 2023.
  • Over the past 5 years, Jazz Pharmaceuticals' Tax Provisions (Quarterly) stood at -$12.5 million in 2021, then plummeted by 701.36% to -$100.0 million in 2022, then spiked by 66.92% to -$33.1 million in 2023, then slumped by 75.02% to -$57.9 million in 2024, then tumbled by 1,568.09% to -$242.4 million in 2025.
  • Its last three reported values are -$242.4 million in Q3 2025, -$17.8 million for Q2 2025, and -$57.9 million during Q4 2024.